Home  |  Contact

UniProtKB/Swiss-Prot Q9GZV3: Variant p.Arg446Gly

High affinity choline transporter 1
Gene: SLC5A7
Variant information

Variant position:  446
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Arginine (R) to Glycine (G) at position 446 (R446G, p.Arg446Gly).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from large size and basic (R) to glycine (G)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In CMS20; decreased choline transmembrane transporter activity; no effect on localization at plasma membrane.
Any additional useful information about the variant.



Sequence information

Variant position:  446
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  580
The length of the canonical sequence.

Location on the sequence:   FVKGTNTYGAVAGYVSGLFL  R ITGGEPYLYLQPLIFYPGYY
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         FVKG-TNTYGAVAGYVSGLFLRITGGEPYLYLQPLIFYPGYY

Mouse                         FIKG-TNTYGAVAGYIFGLFLRITGGEPYLYLQPLIFYPGY

Rat                           FIKG-TNTYGAVAGYIFGLFLRITGGEPYLYLQPLIFYPGY

Caenorhabditis elegans        YMPR-SNTYGSLAGYAVGLVLRLIGGEPLVSLPAFFHYPMY

Drosophila                    HFKKHCNTYGSLSAYIVALAIRLSGGEAILGLAPLIKYPGY

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 580 High affinity choline transporter 1
Transmembrane 436 – 456 Helical
Mutagenesis 451 – 451 E -> Q. Only 5% of wild-type choline uptake activity.


Literature citations

Impaired presynaptic high-affinity choline transporter causes a congenital myasthenic syndrome with episodic apnea.
Bauche S.; O'Regan S.; Azuma Y.; Laffargue F.; McMacken G.; Sternberg D.; Brochier G.; Buon C.; Bouzidi N.; Topf A.; Lacene E.; Remerand G.; Beaufrere A.M.; Pebrel-Richard C.; Thevenon J.; El Chehadeh-Djebbar S.; Faivre L.; Duffourd Y.; Ricci F.; Mongini T.; Fiorillo C.; Astrea G.; Burloiu C.M.; Butoianu N.; Sandu C.; Servais L.; Bonne G.; Nelson I.; Desguerre I.; Nougues M.C.; Boeuf B.; Romero N.; Laporte J.; Boland A.; Lechner D.; Deleuze J.F.; Fontaine B.; Strochlic L.; Lochmuller H.; Eymard B.; Mayer M.; Nicole S.;
Am. J. Hum. Genet. 99:753-761(2016)
Cited for: FUNCTION; SUBCELLULAR LOCATION; INVOLVEMENT IN CMS20; VARIANTS CMS20 GLY-48; GLU-65; SER-105; HIS-111; CYS-175; THR-291; LEU-344; GLN-361; VAL-418 AND GLY-446; CHARACTERIZATION OF VARIANTS CMS20 GLY-48; GLU-65; SER-105; GLN-361 AND GLY-446;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.